Cargando…

Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE

AIMS: The ability to differentiate patient populations with type 2 diabetes at high risk of severe hypoglycaemia could impact clinical decision making. The aim of this study was to develop a risk score, using patient characteristics, that could differentiate between populations with higher and lower...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heller, Simon, Lingvay, Ildiko, Marso, Steven P., Philis‐Tsimikas, Athena, Pieber, Thomas R., Poulter, Neil R., Pratley, Richard E., Hachmann‐Nielsen, Elise, Kvist, Kajsa, Lange, Martin, Moses, Alan C., Trock Andresen, Marie, Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756403/ https://www.ncbi.nlm.nih.gov/pubmed/32996693 http://dx.doi.org/10.1111/dom.14208

Ejemplares similares

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
por: Pieber, Thomas R., et al.
Publicado: (2017)

Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
por: Klein, Klara R, et al.
Publicado: (2021)

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
por: Pratley, Richard E., et al.
Publicado: (2019)

Abstract 4: Derived time-in-range is associated with major adverse cardiovascular event in T2D: Data from the DEVOTE trial
por: Pathan, Muzammil Khan A, et al.
Publicado: (2022)

Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE
por: Bergenstal, Richard M., et al.
Publicado: (2023)

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
por: Pratley, Richard E., et al.
Publicado: (2019)

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)
por: Amod, Aslam, et al.
Publicado: (2020)

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials
por: DeVries, J. Hans, et al.
Publicado: (2018)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
por: Amod, Aslam, et al.
Publicado: (2019)

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2020)

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
por: Pollock, Richard F., et al.
Publicado: (2019)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
por: Pollock, Richard F., et al.
Publicado: (2019)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Digital health tools to promote diabetes education and management of cardiovascular risk factors among under-resourced populations
por: Paul, Tenes, et al.
Publicado: (2021)

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
por: Philis-Tsimikas, Athena
Publicado: (2008)

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2022)

100 years on: the impact of the discovery of insulin on clinical outcomes
por: Buse, John B, et al.
Publicado: (2021)

Periodic Intensive Insulin Therapy Remains Experimental
por: Chang, Amy, et al.
Publicado: (2019)

Devotion
por: McLaughlin, John, 1942-
Publicado: (1992)

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials
por: Rose, Ludger, et al.
Publicado: (2019)

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
por: Buse, John B., et al.
Publicado: (2021)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
por: Pollock, Richard F., et al.
Publicado: (2018)

Devotion to Duty
Publicado: (1906)

Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches: A Project Dulce promotora randomized trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2011)

Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

Devotion for newborn children
por: Purcarea, VL
Publicado: (2016)

Predictors of Dropouts From a San Diego Diabetes Program: A Case Control Study
por: Benoit, Stephen R., et al.
Publicado: (2004)

Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study
por: Benoit, Stephen R, et al.
Publicado: (2005)

Devotions upon emergent occasions
Publicado: (1977)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Improving Treatment of Depression Among Latinos With Diabetes Using Project Dulce and IMPACT
por: Gilmer, Todd P., et al.
Publicado: (2008)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
por: Philis-Tsimikas, Athena, et al.
Publicado: (2013)

Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo‐RESOLVE) project
por: de Galan, B. E., et al.
Publicado: (2020)

The Ordinary Devoted Mother and Her Baby
Publicado: (1950)

Ramadan: devotion, compassion, and purification in Sydney
por: Possamai, Adam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7i2e5rq6r9puaabp2fr2o847i7